PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	10/556,229)
TRANSMITTAL	Filing Date	November 9, 20	lovember 9, 2005	
FORM	First Named Inventor	Besidski, et al		
	Art Unit	Unknown		
(to be used for all correspondence after initial filing)	Examiner Name	Unknown		
Total Number of Pages in This Submission 11	Attorney Docket Number	101062-1P US		
ENCL	OSURES (Check all t	that apply)	***	
Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Ferminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD	ddress	Appeal of Appeal (Appeal (Appeal Status I Other Ebelow):	Enclosure(s) (please Identify B/08A and Form PTO/SB/08B
	OF APPLICANT, ATTOI	RNEY, OR A	AGENT	
Firm Name AstraZeneca Pharmaceuticels (add	ress associated with Custome	er No. 22466)		
Signature	1 dall			
Printed name Kenneth F. Mitchell				
Date May 23, 2	(20) F	Reg. No. 42	,007	
CERTIFICATE OF TRANSMISSION/MAILING				
I hereby certify that this correspondence is being facsi sufficient postage as first class mail in an envelope ad the date shown below:				
Signature	Grelock)		
Typed or printed name Marie M. Greloch			Date	MAY 23, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IAP12 Rec'd PCT/PTO 25 MAY 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/556,229 Confirmation No.: Unknown

Applicant: Besidski, et al. PCT Appl. No.: PCT/SE2004/000738

National Phase Fld (371): November 9, 2005 PCT Filed: May 13, 2004

Docket No.: 101062-1P US TC/A.U.: Unknown

Customer No.:22466 Examiner: Unknown

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p). However, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to Deposit Account No. 260166 referencing Attorney Docket No. 101062-1P US.

Respectfully submitted,

Kenneth F. Mitchell Reg. No.42,007

302-886-7466

May 23, 2006

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

SIAIEMENI BY APPLICANI
(Use as many sheets as necessary)

Sheet 1 of 4 Attorney Docket Number 101062-1P US

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	^{US-} 3,624,103	11-30-1971	Franco De Martiis	
	A2	^{US-} 4,738,981 A	04-19-1988	Horwell	
	A3	^{US-} 6,794,404 B2	09-21-2004	Beaulieu, et al.	
		US-			
-		US-			
	 	US-			
	†	US-			

		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	A4	WO 03/049702	06-19-2003	Amgem Inc.		
	A5	WO 04/024154 A1	03-25-2004	Glaxo Grp Limited		
	A6	WO 99/00115	01-07-1999	Smithkline Beecham PLC		
	A7	WO 03/014064 A1	02-20-2003	Bayer Aktiengesellschaft		
	A8	WO 02/50031 A1	06-27-2002	Glaxo Grp Limited		
	A9	WO 01/12189 A1	02-22-2001	Pharmacia & UpJohn S.P.A.		Г

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION	DISCL	.OSUR	E

Substitute for form 1449/PTO

STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known				
Application Number	10/556,229			
Filing Date	November 9, 2005			
First Named Inventor	Yevgeni BESIDSKI			
Art Unit	Not Known			
Examiner Name	Not Known			
Attorney Docket Number	101062-1P US			

		T	U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US-			rigures Appear
	<u> </u>	US-	 		
		US-			
		US-	 		
		US-		 	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-	1	· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-	 		

		FORE	IGN PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	7 phoenical of Orica bocament	Or Relevant Figures Appear	T ⁶
_		WO 94/22859	10-13-1994	Bayer Aktiengesellschaft		
	A11	WO 04/000828 A1	12-31-2003	Biovitrum AB		
		WO 02/100822 A1	12-19-2002	Biovitrum AB		
	A13	WO 01/96336 A2	12-20-2001	Warner-Lambert Co		-
	A14	WO 01/85722 A1	11-15-2001	Cor Therapeutics, Inc.		
	A15	GB 1,186,504		Fisons Pest Control Lmtd		-

Examiner	
Signature Date Capital de la C	
Considered	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Trainstation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

To: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

101062-1P US

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

Application Number 10/556,229

Filing Date November 9, 2005

First Named Inventor Yevgeni BESIDSKI

Art Unit Not Known

Examiner Name Not Known

Sheet

of

Attorney Docket Number

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code ^{2 (2 known)}			Figures Appear	
		US-				
		US-				
		US-				
		US-				
-	<u> </u>	US-				
	<u> </u>	US-				
	<u> </u>	US-				
	 	US-		· · · · · · · · · · · · · · · · · · ·		
	<u> </u>	US-				
		US-				
	†	US-				
		US-				
,		US-				
		US-				
		US-				
		US-		·		
		US-				
	†	US-				
	\dagger	US-	-1			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	A16	WO 03/068749 A1	08-21-2003	Glaxo Group Limited		
	A17	WO 04/024710	03-25-2004	Glaxo Group Limited		
	A18	WO 03/022809 A2	03-20-2003	SmithKline Beecham PLC		
	A19	WO 03/053945 A2	07-03-2003	SmithKline Beecham PLC		
	A20	WO 02/090326 A1	11-14-2002	SmithKline Beecham PLC		
	A21	WO 02/072536 A1	09-19-2002	SmithKline Beecham PLC		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/556,229 Filing Date November 9, 2005 INFORMATION DISCLOSURE First Named Inventor Yevgeni BESIDSKI STATEMENT BY APPLICANT Art Unit Not Known (Use as many sheets as necessary) **Examiner Name** Not Known 101062-1P US Attorney Docket Number

			U. S. PATENT D	OCUMENTS	· ·	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan	
		Number-Kind Code ^{2 (# known)}		· ·	Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
-		US-				
		US-				
-		US-			· · · · · · · · · · · · · · · · · · ·	
	1	US-				
	1	US-				
	1	US-				
	1	US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ,		
	A22	EP 1 312 601 A1	05-21-2003	Ono Pharmaceutical Co				
	A23	EP 0 419 210 A1	03-27-1991	Pfizer Inc				
	A24	EP 0 149 200	12-20-1984	Dr. Karl Thomae GmbH				
						L		
1						П		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 1449B/PTO				Complete if Known		
				Application Number	10/556,229		
INFO	RMATION D)ISCLO	SURE	Filing Date	11/09/2005		
STAT	EMENT BY	APPLI	CANT	First Named Inventor	Yevgeni Besidski		
		•		Art Unit	Not		
	(Use as many sheets	as necessary)		Examiner Name	Not Known		
Sheet	1	of	_ 4_	Attorney Docket Number	101062-1P US		

:		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	A25	MCDONNELL, et al., "7-Hydroxynaphthalen-1-yl-Urea and -Amide Antagonists of Human Vanilloid Receptor 1"; Bioorganic & Medicinal Chemistry Letters 14 (2004), pgs 531-534	
	A26	MUSSO, et al., "Indanylidenes. 1. Design and Synthesis of and Analgesic Activity"; J. Med. Chem 2003, 46, pgs 399-408	
	A27	YIANGOU, et al., "Capsaicin Receptor VR1 and ATP-Gated ion Channel P2X3, in Human Urinary Bladder"; BJU International (2001), 87, pgs 774-779	•
	A28	WALKER, et al., "The VR1 Antagonist Capsazepine Inflammatory and Neuropathic Pain"; J. Pharmacology & Experimental Therapeutics, Vol. 304, No. 1, pgs 56-62	
	A29	RASHID, et al., "Novel Expression of Vanilloid in Neuropathic Pain"; J. Pharmacology & Experimental Therapeutics, vol 304, No. 3, pgs 940-948	
	A30	CATERINA, et al., "The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway"; Nature, Vol 389, Oct 23, 1997, pgs 816-824	**********
•	A31	TOMINAGA, et al., "The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli"; Neuron, Vol 21, September 1998, pgs 531-543	
	A32	HWANG, et al., "Hot Channels in Airways: Pharmacology of the Vanilloid Receptor"; Respiratory, Curr Opin Pharmacol 2002, June, 2(3) pgs 235-242	***********
	A33	SZALLASI, et al. "Vanilloid (Capsaicin) Receptors in Health and Disease"; Am J Clin Pathol 2002, 118, pgs 110-121	**********
	A34	T.L. GILCHRIST, "Heterocyclic Chemistry", 2nd Edition, Longman Scientific and Technical (1992), pgs 248-282	******

			<u> </u>
Examiner		Date	
Signature			
Signature		Considered	j

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. 'Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for fo	orm 1449B/PTO				Complete if Known	
				Application Number	10/556,229	
INFOR	MATION DI	SCLO	SURE	Filing Date	11/09/2005	
STATE	MENT BY	APPLI	CANT	First Named Inventor	Yevgeni Besidski	
				Art Unit	Not	
(L	Jse as many sheets as	necessary))	Examiner Name	Not Known	
Sheet	<u> </u>	of	<i>Y</i>	Attorney Docket Number	101062-1P US	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	A35	B. Bijaya Kumar, V. Malla Reddy, Indian Journal of Chemistry, Vol 24B, Oct 1985, pgs 1098-1101, Table 1, Scheme I					
	A36	Anthony Gallard, et al., Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 18, No. 2. 2003, "New N-Pyridinyl(methyl)-N1-Substituted Systemic anti-Inflammatory Agents", pgs 201-208					
<i>-</i> -	A37	STN International, Accession No. 200:912544, 24 April 2003, CHS 0297096, "1H-Benzimidazole-1-acetamide, N-[3-(trifluoromethyl)phenyl]-CAS Registry No. 294669-15-1					
	A38	STN International, Accession No. 2000:532079, 23 april 2003, BAS 0238979, "1H-Benzimidazole-1-acetamide, N-(3-chlorophenyl)-CAS Registry No. 116488-26-7					
	A39	STN International, Accession No. 2001:10738, 24 April 2003, NS11937, "1H-Indole-3-butanamide, N-(4-methylphenyl)-CAS Registry No. 313550-48-0					
	A40	STN International, Accession No. 2001:1505160, 29 April 2003, AG-690/40696518, "1H-Benzimidazole-1-acetamide,N-(2,3-dichlorophenyl)-, CAS Registry No. 332384-60-8					
	A41	STN International, Accession No. 2002:2035573, 09 July 2002, ASN 1816063, "1H-Benzimidazole-1-acetamide,N-(3-chloro-4-methylphenyl)" -CAS Registry No. 332908-87-9					
	A42	STN International, Accession No. 2002;2042451, 09 July 2002, ASN 4428244, "1H-Benzimidazole-1-acetamide,N-(5-amino-2-methylphenyl)" - CAS registry No. 436095-70-4					
	A43	STN International, Accession No. 2003:454497, 30 April 2003, ASN 5212034, "1H-Indole-3-acetamide, N-[4-(1-methylethyl)phenyl]" - CAS Registry No. 460336-68-9					
	A44	STN International, Accession No. 2003:454500, 30 april 2003, ASN 5212038, 1H-Indole-3-acetamide, N-(3,5-dimethoxyphenyl)" - CAS Registry No. 460336-71-4					

$\overline{}$	 	I		
Examiner			Date	
Signature			Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO	L	Complete if Known		
	Application Number	10/556,229		
INFORMATION DISCLOSURE	Filing Date	11/09/2005		
STATEMENT BY APPLICANT	First Named Inventor	Yevgeni Besidski		
	Art Unit	Not		
(Use as many sheets as necessary)	Examiner Name	Not Known		
Sheet 3 of 4	Attorney Docket Number	101062-1P US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the iter magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), published and/or country where published.		T ²
	A45	STN International, Accession No. 2003:1778448, 09 July 2002, ASN 3067491, "1H-Benzimidazole-1-acetamide, N-(2-flurophenyl)" - CAS Registry No. 483326-88-1	
	A46	STN International, Accession No. 2003:1780032, 09 July 2002, ASN 3110045, "1H-Benzimidazole-1-acetamide, 5,6-dimethyl-N-[2-(trifluoromethyl)phenyl]" - CAS Registry No. 483347-09-7	
	A47	STN International, Accession No. 2003:1780036, 09 July 2002, ASN 3110053, "1H-Benzimidazole-1-acetamide,N-(2,4-dimethoxyphenyl)-5,6-dimethyl" - CAS Registry No. 483347-12-2	
	A48	STN International, Accession No. 2003:1780041, 09 July 2002, ASN 3110088, "1H-Benzimidazole-1-acetamide, "N-[4-(dimethylamino)phenyl]-5,6-dimethyl" - CAS Registry No. 483347-17-7	
	A49	STN International, Accession No. 2003:1783073, 09 July 2002, ASN 3212475, "1H-Benzimidazole-1-acetamide, N-(3-fluorophenyl)" - CAS Registry No. 483978-05-8	
	A50	STN International, Accession No. 2003:2842871, 30 April 2003, BAS 5595011, "1H-Indole-3-acetamide, N-(3-fluoro-4-methylphenyl)" - CAS Registry No. 510764-85-9	
	A 51	STN International, Accession No. 2003:3562090, 30 April 2003, ZT-5586656, "1H-Indole-3-propanamide,N-[2-(1-methylethyl)phenyl]" - CAS Registry No. 556791-23-2	
	A52	STN International, Accession No. 2003:3425665, 30 April 2003, ZT-2132403, "1H-Indole-3-propanamide, N-[4-(1,1-dimethylethyl)phenyl]" - CAS Registry No. 562052-38-4	1
	A53	STN International, Accession No. 2003:3428083, 30 April 2003, ZT-2150185, "1H-Indole-3-propanamide, N-(2-chloro-4-methylphenyl)" - CAS Registry No. 562794-00-7	
	A54	STN International, Accession No. 2002:737351, document no. 138:265138, Olgen, Sureyya, et al., "Synthesis and indole-3-acetamide derivatives", & Archiv der Pharmazie (Weinheim, Germany) (2002), 335(7), 331-338	

-			
	Examiner	Date	
	Signature	Considered Considered	J

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449B/PTO				Complete if Known			
					Application Number	10/556,229		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					Filing Date			
					First Named Inventor	Yevgeni Besidski		
					Art Unit	Not		
					Examiner Name	Not Known		
abla	Sheet	4	of	4	Attorney Docket Number	101062-1P US		

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. STN International, Accession No. 2002:695939, document no. 137:232452, Rotta Research Lab, S.p.A., "Preparation of benzamidines having antiinflammatory & immunosuppressive activity", & WO2002070468,A2,20020912 STN International, Accession No. 2000:825244, document no. 134:147129, Jamieson, Craig, et al., "A rapid approach for the optimization of polymer supported reagents in synthesis", & Synlett (2000), (11), 1603-1607 STN International, Accession No. 1988:610992, document no. 109:210992, Shah, V.H., et al., "Studies on accetamide derivatives. Part-II. Preparation sulfamethazin-4-yl/acetamides", & Jr of the Indian Chemical
"Preparation of benzamidines having antiinflammatory & immunosuppressive activity", & WO2002070468,A2,20020912 STN International, Accession No. 2000:825244, document no. 134:147129, Jamieson, Craig, et al., "A rapid approach for the optimization of polymer supported reagents in synthesis", & Synlett (2000), (11), 1603-1607 STN International, Accession No. 1988:610992, document no. 109:210992, Shah, V.H., et al., "Studies on
approach for the optimization of polymer supported reagents in synthesis", & Synlett (2000), (11), 1603-1607 STN International, Accession No. 1988:610992, document no. 109:210992, Shah, V.H., et al., "Studies on
Society (1987), 64(11), 678-81
STN International, Accession No. 1958:31856, document n o. 52:31856, Cacace, Fulvio, et al., "Benzimidazole-N-acetic growth activity", & Atti accad. nazl. Lincei. Rend., Classe sci. fiz., mat. e nat. (1957), 22, 510-13
STN International, Accession No. 1993:102385, document no. 118:102385, Gallant, Michel, et al., "A stereoselective synthesis of rebeccamycin", & Jr of Organic Chemistry (1993), 58(2), 343-9
STN International, Accession No. 1998:227318, document no. 128:308402, Sanwa Kagaku Kenkyusho Co., Ltd., "Preparation of as antiarteriosclerotics", & JP, A2, 10095766, 19980414
STN International, Accession No. 1995:594439, document no. 123:9266, Interneuron Pharm, Inc., "Substituted tryptamines and related compounds", & US,A,5403851,19950404
International Search Report for International Application No.PCT/SE2004/000738
International-Type Search Report
5

<i>'</i>		
C	I B - 4 -	
Examiner	Date	
Signature	Considered	
Cignature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.